Although the peptide-based p53 aggregation inhibitor ReACp53 reportedly increased carboplatin efficacy in HGSOC (29), the contribution of transcellular spreading to resistance to platinum chemotherapy in p53-mutated cancer is yet to be elucidated. This evidence concerns the gene TP53 and cancer.